How Could In Vitro Antiviral Activity Be Applied to Optimize the Dosing Regimens of Candidates for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)?
作者信息
Jia Ranran, Wang Hongyun
机构信息
Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Damucang Hutong, Xicheng District, Beijing, China.
出版信息
Clin Infect Dis. 2021 Jul 15;73(2):352-353. doi: 10.1093/cid/ciaa1325.
Abstract
摘要
相似文献
1
How Could In Vitro Antiviral Activity Be Applied to Optimize the Dosing Regimens of Candidates for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)?如何将体外抗病毒活性应用于优化严重急性呼吸综合征冠状病毒2（SARS-CoV-2）治疗候选药物的给药方案？
Clin Infect Dis. 2021 Jul 15;73(2):352-353. doi: 10.1093/cid/ciaa1325.
2
In Vitro Antiviral Activity of Nordihydroguaiaretic Acid against SARS-CoV-2.北地愈创木薁醇对 SARS-CoV-2 的体外抗病毒活性。
Viruses. 2023 May 11;15(5):1155. doi: 10.3390/v15051155.
3
Antiviral Activity of the Propylamylatin Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions.采用直接注射和气体检测法在病毒悬浮液中评估丙戊酰拉亭配方对新型冠状病毒 SARS-CoV-2 的抗病毒活性
Viruses. 2021 Mar 5;13(3):415. doi: 10.3390/v13030415.
4
Isolation of SARS-CoV-2 from COVID-19 Patients and an Asymptomatic Individual.从新冠肺炎患者及一名无症状感染者中分离出严重急性呼吸综合征冠状病毒2。
Jpn J Infect Dis. 2022 May 24;75(3):277-280. doi: 10.7883/yoken.JJID.2021.292. Epub 2021 Oct 29.
5
Lithium for the 2019 novel coronavirus.锂用于治疗2019新型冠状病毒。 （不过从专业角度看，该表述不太符合医学常理，可能存在信息偏差，仅按要求翻译）
Med Hypotheses. 2020 Sep;142:109822. doi: 10.1016/j.mehy.2020.109822. Epub 2020 May 7.
6
Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection.干扰素-β-1a 对病毒感染后给药时体外严重急性呼吸综合征冠状病毒 2 的抑制作用。
J Infect Dis. 2020 Aug 4;222(5):722-725. doi: 10.1093/infdis/jiaa350.
7
Replication of Severe Acute Respiratory Syndrome Coronavirus 2 in Human Respiratory Epithelium.严重急性呼吸综合征冠状病毒 2 在人呼吸道上皮细胞中的复制。
J Virol. 2020 Jul 16;94(15). doi: 10.1128/JVI.00957-20.
8
Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing.用于高通量抗病毒筛选和测试的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）报告基因复制子的构建
Proc Natl Acad Sci U S A. 2021 Apr 13;118(15). doi: 10.1073/pnas.2025866118.
9
Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL Reporter Assay.基于荧光的高通量 SARS-CoV-2 3CL 报告酶测定法的建立。
J Virol. 2020 Oct 27;94(22). doi: 10.1128/JVI.01265-20.
10
Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.用于筛选针对 SARS-CoV-2 的中和抗体和抗病毒药物的快速体外检测方法。
J Virol Methods. 2021 Jan;287:113995. doi: 10.1016/j.jviromet.2020.113995. Epub 2020 Oct 14.
引用本文的文献
1
The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2.CT-P59 在体外和体内对 SARS-CoV-2 的 Gamma、Delta 及其相关变体的疗效。
Biochem Biophys Res Commun. 2021 Nov 12;578:91-96. doi: 10.1016/j.bbrc.2021.09.023. Epub 2021 Sep 13.
2
Response to Jia and Wang.对贾和王的回应。
Clin Infect Dis. 2021 Jul 15;73(2):352-353. doi: 10.1093/cid/ciaa1390.
本文引用的文献
1
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.羟氯喹在非人类灵长类动物中对抗 SARS-CoV-2 感染的应用。
Nature. 2020 Sep;585(7826):584-587. doi: 10.1038/s41586-020-2558-4. Epub 2020 Jul 22.
2
Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019.将羟氯喹的体外抗病毒活性与体内浓度相关联，以预测其抗病毒效果：这是治疗 2019 年冠状病毒病患者的关键步骤。
Clin Infect Dis. 2020 Dec 15;71(12):3232-3236. doi: 10.1093/cid/ciaa623.
3
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.羟氯喹啉是氯喹毒性较低的衍生物，在体外可有效抑制严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染。
Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020.
4
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
5
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
6
Kinetics of chloroquine uptake into isolated rat hepatocytes.氯喹摄取进入分离的大鼠肝细胞的动力学。
J Pharm Sci. 1993 Jun;82(6):592-600. doi: 10.1002/jps.2600820610.
7
Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate.硫酸羟氯喹的动物毒性和药代动力学
Am J Med. 1983 Jul 18;75(1A):11-8. doi: 10.1016/0002-9343(83)91265-2.
8
Tissue distribution of chloroquine, hydroxychloroquine, and desethylchloroquine in the rat.氯喹、羟氯喹和去乙基氯喹在大鼠体内的组织分布
Toxicol Appl Pharmacol. 1967 May;10(3):501-13. doi: 10.1016/0041-008x(67)90089-0.
9
Metabolism of chloroquine and hydroxychloroquine in albino and pigmented rats.氯喹和羟氯喹在白化病大鼠和有色大鼠体内的代谢
Toxicol Appl Pharmacol. 1965 Jul;7(4):627-36. doi: 10.1016/0041-008x(65)90050-5.
Zotero 插件